Emergent BioSolutions Q1 2026 Financial Results

Emergent BioSolutions reported first quarter 2026 revenues of $156.1 million, with a net income of $6.8 million and a net income margin of 4%. Adjusted EBITDA was $35.6 million, representing a 23% margin. The company highlighted strong performance in its Medical Countermeasures (MCM) segment, with international sales constituting 37% of total MCM revenue in Q1. They also maintained market share in the naloxone category and launched new product presentations for NARCAN® Nasal Spray. Strategic initiatives include new manufacturing agreements with Substipharm Biologics for a Japanese Encephalitis vaccine and with SAB Biotherapeutics for a type 1 diabetes candidate. The company refinanced its term loan, extending the maturity to 2031 and reducing interest expenses. Emergent BioSolutions updated its full-year 2026 financial forecast, projecting revenues between $720-$760 million and Adjusted EBITDA of $155-$175 million. They also anticipate Adjusted Net Income to be in the range of $45-$65 million. The company ended the quarter with $160.3 million in cash and cash equivalents and $260 million in liquidity.